Marie Lindgren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marie Lindgren has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Björn Andréasson
Hematology and Coagulation Section, Department of Medicine, Sahlgrenska University Hospital, Göteborg
2 shared publications Helna Pettersson
Division of Hematology Specialist Medicine NU Hospital Group Uddevalla Sweden
2 shared publications- Anna Ravn Landtblom
Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
1 shared publication Björn Andreasson
Hematology section, Medical Clinic, NU hospital organization, Uddevalla Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg
1 shared publication- Erik Ahlstrand
Department of Medicine, Faculty of Medicine and Health, Örebro University, 70382 Örebro, Sweden
1 shared publication Håvar Knutsen
Department of Hematology Ullevål University Hospital Oslo Norway
1 shared publication
Latest Publications
- 20 December 2019
- Published by Wiley in European Journal of Haematology
- Vol. 104 (3) , 271-278
Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up
Objective: To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV).Methods: Nested case‐control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls.Results: Incidence of vascular complications was 2.0 and 3.4 events per 100 patient‐years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti‐thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls.Conclusions: The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti‐thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.
- 20 December 2019
- Published by Wiley in European Journal of Haematology
- Vol. 104 (3) , 271-278
Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up
Objective: To explore the relative importance of risk factors, treatments, and blood counts for the occurrence of vascular complications and their impact on life expectancy in essential thrombocythemia (ET) and polycythemia vera (PV).Methods: Nested case‐control study within the Swedish MPN registry. From a cohort of 922 ET patients and 763 PV patients, 71 ET and 81 PV cases with vascular complications were compared with matched controls.Results: Incidence of vascular complications was 2.0 and 3.4 events per 100 patient‐years in ET and PV, respectively. At diagnosis, no significant risk factor differences were observed between cases and controls in neither of the diseases. At the time of vascular event, ET complication cases did not differ significantly from controls but in PV, cases had significantly higher WBCs and were to a lesser extent treated with anti‐thrombotic and cytoreductive therapy. Life expectancy was significantly decreased in both ET and PV cases compared with controls.Conclusions: The risk of vascular complications is high in both ET and PV, and these complications have a considerable impact on life expectancy. The protective effect of anti‐thrombotic and cytoreductive therapy for vascular complications in PV underscores the importance of avoiding undertreatment.
- 25 January 2018
- Published by Wiley in European Journal of Haematology
- Vol. 100 (5) , 419-425
Genetic variation in IL28B (IFNL3) and response to interferon‐alpha treatment in myeloproliferative neoplasms
Objective: In myeloproliferative neoplasms (MPN), interferon‐alpha (IFN‐α) is an effective treatment with disease‐modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN‐α treatment. In this study, we sought to evaluate the prognostic impact of IL28B rs12979860, rs8099917, and rs12980275 on IFN‐α treatment response in myeloproliferative neoplasms.Method: We retrospectively evaluated 100 patients with MPN treated with IFN‐α. The hematologic treatment response on IFN‐α was compared between patients and correlated with host genetic variations in IL28B. The genotypes of IL28B were determined by allelic discrimination assays.Results: The CC genotype of rs12979860 was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non‐CC), (P = .036). No association between the genotypes and treatment response on hydroxyurea was found.Conclusion: These results imply an effect of IL28B genotype on the outcome of IFN‐α treatment in MPN.
- 25 January 2018
- Published by Wiley in European Journal of Haematology
- Vol. 100 (5) , 419-425
Genetic variation in IL28B (IFNL3) and response to interferon‐alpha treatment in myeloproliferative neoplasms
Objective: In myeloproliferative neoplasms (MPN), interferon‐alpha (IFN‐α) is an effective treatment with disease‐modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN‐α treatment. In this study, we sought to evaluate the prognostic impact of IL28B rs12979860, rs8099917, and rs12980275 on IFN‐α treatment response in myeloproliferative neoplasms.Method: We retrospectively evaluated 100 patients with MPN treated with IFN‐α. The hematologic treatment response on IFN‐α was compared between patients and correlated with host genetic variations in IL28B. The genotypes of IL28B were determined by allelic discrimination assays.Results: The CC genotype of rs12979860 was found significantly associated with hematologic response in polycythemia vera (PV) with a complete response (CR) in 79% (CC) compared to 48% (non‐CC), (P = .036). No association between the genotypes and treatment response on hydroxyurea was found.Conclusion: These results imply an effect of IL28B genotype on the outcome of IFN‐α treatment in MPN.
- Open Access
- 4 September 2012
- Published by Sciedu Press in Journal of Hematological Malignancies
- Vol. 2 (3) , p18
Influence of interferon-α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B
Background: Interferon-α (IFN-α) is a therapeutic option in high risk patients with Myeloproliferative Neoplasms (MPNs). The response to IFN-α treatment of chronic hepatitis C was shown to be strongly influenced by several related single nucleotide polymorphisms (SNP) in a region adjacent to the IL28B gene. The objective of this study was to investigate the possibility of similar influence of IL28B gene polymorphism in IFN-α treated MPN patients. Methods: 20 patients with polycythemia vera (PV) or essential thrombocythemia (ET) treated with IFN-α included, 7 were earlier treated with hydroxyurea. Hematologic response was evaluated using the European Leukemia Net (ELN) criteria. DNA from whole blood samples was isolated using MagNA Pure LC DNA Isolation Kit I for IL28B genotyping, and the variability at rs12979860, rs12980275 and rs8099917 were determined by allelic discrimination assays using Taqman minor groove binding probes. Results: The IFN-α treatment reduced platelet count (ppp=0.010). Conclusion: The results in this pilot study indicate that variation in IL28B genotype might influence hematologic response in IFN-α treated MPN patients.
- 4 September 2012
- Published by Sciedu Press in Journal of Hematological Malignancies
- Vol. 2 (3) , p18
Open AccessInfluence of interferon-α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B
Background: Interferon-α (IFN-α) is a therapeutic option in high risk patients with Myeloproliferative Neoplasms (MPNs). The response to IFN-α treatment of chronic hepatitis C was shown to be strongly influenced by several related single nucleotide polymorphisms (SNP) in a region adjacent to the IL28B gene. The objective of this study was to investigate the possibility of similar influence of IL28B gene polymorphism in IFN-α treated MPN patients. Methods: 20 patients with polycythemia vera (PV) or essential thrombocythemia (ET) treated with IFN-α included, 7 were earlier treated with hydroxyurea. Hematologic response was evaluated using the European Leukemia Net (ELN) criteria. DNA from whole blood samples was isolated using MagNA Pure LC DNA Isolation Kit I for IL28B genotyping, and the variability at rs12979860, rs12980275 and rs8099917 were determined by allelic discrimination assays using Taqman minor groove binding probes. Results: The IFN-α treatment reduced platelet count (ppp=0.010). Conclusion: The results in this pilot study indicate that variation in IL28B genotype might influence hematologic response in IFN-α treated MPN patients.